“Pediatricians have been especially receptive to the steroid-free profile of EpiCeram® for managing this often chronic skin condition.”
South Plainfield, N.J. (PRWEB) November 09, 2011
PuraCap™ Pharmaceutical LLC (http://www.PuraCap.com), an emerging, fully-integrated pharmaceutical company with expertise in product development, manufacturing and bringing affordable, world-class quality products to their customers, announces the acquisition of their first prescription brand, EpiCeram® Skin Barrier Emulsion (http://www.EpiCeram-US.com).
Launched in 2008, EpiCeram® is a steroid-free, fragrance-free, and non-greasy treatment for the relief of the burning and itching associated with various types of dermatoses, including atopic dermatitis, irritant dermatitis, and radiation dermatitis. According to the American Academy of Dermatology, between 10% - 20% percent of children and 1% - 3% of adults world-wide have atopic dermatitis, with 90% of the cases presenting before the age of five years.
In a clinical study, EpiCeram® was shown to effectively relieve the signs and symptoms of atopic dermatitis with comparable efficacy to a mid-potency topical steroid cream after twenty-eight days of treatment. EpiCeram® aims to repair the skin’s natural barrier with a lipid-based formulation which has a 3:1:1 ratio of ceramide, cholesterol, and fatty acids, similar to that found in normal skin.
“Steroids have been the mainstay treatment for atopic dermatitis, but they can have systemic effects when used long term,” commented Jeff Thomas, Chief Commercial Officer of PuraCap™ Pharmaceutical. “Pediatricians have been especially receptive to the steroid-free profile of EpiCeram® for managing this often chronic skin condition.”
“We are excited to launch our national pharmaceutical sales team with our first prescription brand under the PuraCap™ label,” commented Dahai Guo, Chief Executive Officer, PuraCap™ Pharmaceutical. “We look forward to expanding our global presence and branded portfolio with other unique products in the dermatologic and pediatric therapeutic areas.”
Please see attached EpiCeram® Skin Barrier Emulsion Patient Information sheet for full prescribing information and contraindications. For more information, visit http://www.EpiCeram-US.com.
About PuraCap™ Pharmaceutical LLC - PuraCap™ Pharmaceutical LLC is an emerging, fully-integrated pharmaceutical company with expertise in product development, manufacturing and bringing affordable, world-class quality products to their customers. The PuraCap™ corporate structure supports their three-prong approach for global growth with dedicated companies in the areas of prescription brands, PuraCap™ Pharmaceutical LLC; prescription generics, PuraCap™ Laboratories Inc.; and OTC and Private Label products, PuraVation™ Pharmaceuticals Inc. For more information on PuraCap™ Pharmaceutical LLC, visit the company's website at http://www.PuraCap.com.
 PuraCap™ Pharmaceutical LLC, (2011). EpiCeram® prescribing information. South Plainfield, NJ: Author.
 American Academy of Dematology website http://www.aad.org.
 Sugarman, J.L., & Parish, L.C., (2009). Efficacy of a lipid-based barrier repair in moderate- to- severe pediatric atopic dermatitis. Journal of Drugs in Dermatology, 8 (12), 1106-1111.
 Bikowski, J. (2009). Understanding the structure, function, and strategies for the repair of the epidermal barrier. Practical Dermatology, 8 (2), 17-18.